Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Diamedica Therapeutics ( (DMAC) ) just unveiled an update.
DiaMedica Therapeutics announced updates to its ReMEDy2 trial for acute ischemic stroke, including expanding the patient pool and increasing interim analysis size, aimed at enhancing trial success and reducing costs. The company also reported regulatory approval for a Phase 2 trial of DM199 for preeclampsia in South Africa. Financially, DiaMedica has $50.2 million in cash and investments, with increased R&D expenses reflecting ongoing trial expansions.
Learn more about DMAC stock on TipRanks’ Stock Analysis page.
